Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration

Expert Opinion on Drug Safety

Volumn 4, Issue 4, 2005, Pages 779-794

  Ulbricht, Catherine ^a   Basch, Ethan ^b   Boon, Heather ^c   Ernst, Edzard ^d   Hammerness, Paul ^e   Sollars, David ^f   Tsourounis, Candy ^g   Woods, Jen ^h   Bent, Stephen ^g  

^a Natural Standard   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF EXETER   (United Kingdom)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Anxiolytic; Dihydrokawain; Dihydromethysticin; Hepatotoxicity; Herb; Kava; Kawain; Methystici; Piper methysticum; Safety; Yangona

Indexed keywords

5 HYDROXYTRYPTOPHAN; ACETAZOLAMIDE; ALCOHOL; ALKALOID; ALPRAZOLAM; AMILORIDE; AMIODARONE; ANABOLIC AGENT; ANESTHETIC AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; ANXIOLYTIC AGENT; BARBITURIC ACID DERIVATIVE; BENAZEPRIL; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CALAMUS EXTRACT; CALENDULA EXTRACT; CAPSICUM EXTRACT; CAPTOPRIL; CARROT EXTRACT; CATNIP; CATNIP EXTRACT; CELERY EXTRACT; CENTRAL DEPRESSANT AGENT; CHROMIUM; CIMETIDINE; CLOBAZAM; CORNUS EXTRACT; COUCH GRASS EXTRACT; CYTOCHROME P450; DEXTROPROPOXYPHENE; DIAZEPAM; DIHYDROKAWAIN; DIHYDROMETHYSTICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DROPERIDOL; ECHINACEA EXTRACT; ELECAMPANE EXTRACT; EPHEDRA EXTRACT; ESCHSCHOLTZIA EXTRACT; FENUGREEK EXTRACT; FLAVANOID; FLUOXETINE; FLUVOXAMINE; FUROSEMIDE; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GOTU KOLA EXTRACT; GUARANA EXTRACT; HALOPERIDOL; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; KAVA EXTRACT; KAVALACTONE; KAWAIN; KETOCONAZOLE; LACTONE DERIVATIVE; LEITAN; LEMON BALM EXTRACT; LETTUCE EXTRACT; LI 150; LISINOPRIL; MATRICARIA EXTRACT; MELATONIN; METHOTREXATE; METHYSTICIN; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OPIPRAMOL; OXYCODONE; PARACETAMOL; PAROXETINE; PHENELZINE; PHENYLALANINE; PIPERMETHYSTINE; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; PRASTERONE; PRIMROSE OIL; PYRIDOXINE; PYRONE DERIVATIVE; QUINAPRIL; RAMIPRIL; RESIN; RISPERIDONE; S ADENOSYLMETHIONINE; SAGE EXTRACT; SASSAFRAS EXTRACT; SCULLCAP EXTRACT; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SHEPHERD PURSE EXTRACT; TERAZOSIN; TRANYLCYPROMINE; TYRAMINE; TYROSINE; UNCLASSIFIED DRUG; URTICA DIOICA EXTRACT; VALERIAN; WITHANIA EXTRACT; YANGONIN; YERBA MANSA EXTRACT; YOHIMBINE;

ANXIETY DISORDER; APATHY; CARROT; CELERY; CHOREOATHETOSIS; CLINICAL TRIAL; CONTACT DERMATITIS; CORNUS; COUCH GRASS; DIAPHORESIS; DISEASE EXACERBATION; DISORIENTATION; DROWSINESS; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MILK LEVEL; DRUG POTENTIATION; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; DYSKINESIA; DYSPNEA; ECG ABNORMALITY; ELECAMPANE; EPIGASTRIC PAIN; ERYTHEMA; ESCHSCHOLTZIA; EXTRAPYRAMIDAL SYMPTOM; EYE IRRITATION; FATIGUE; FENUGREEK; GASTROINTESTINAL SYMPTOM; GOTU KOLA; GUARANA; HERBAL MEDICINE; HOPS; HUMAN; HYDRASTIS; HYDRASTIS EXTRACT; HYPERTENSIVE CRISIS; HYPOALBUMINEMIA; LEMON BALM; LETHARGY; LETTUCE; LIVER CIRRHOSIS; LIVER NECROSIS; LIVER TOXICITY; LYMPHOCYTOPENIA; MATRICARIA; MEDICINAL PLANT; MENINX DISORDER; META ANALYSIS; MUSCLE CRAMP; MUSCLE WEAKNESS; NAUSEA; NEUROTOXICITY; NONHUMAN; OCULOGYRIC CRISIS; PARKINSONISM; PEPPER; PIPER METHYSTICUM; POLYCYTHEMIA; POSTMARKETING SURVEILLANCE; PULMONARY HYPERTENSION; REVIEW; RHABDOMYOLYSIS; SAGE; SASSAFRAS; SCULLCAP; SHEPERD PURSE; SKIN MANIFESTATION; SKIN TOXICITY; SUDDEN DEATH; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOCYTOPENIA; TORTICOLLIS; TOXIC HEPATITIS; TOXICITY TESTING; TREMOR; URTICA DIOICA; UTERUS DISEASE; VISUAL DISORDER; VISUAL IMPAIRMENT; WITHANIA; YERBA;

DATA COLLECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; KAVA; PLANT PREPARATIONS;

EID: 21744457082     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.4.779     Document Type: Review

References (139)

1. STAFFORD N: Germany may ban kava kava herbal supplement, Reuter's News Service Germany (November 19, 2001).
2. MILLS E, SINGH R, ROSS C et al.: Sale of kava extract in some health food stores. CMAJ (2003) 169(11):1158-1159.
3. MILLS SY, STEINHOFF B: Kava-kava: a lesson for the phytomedicine community. Phytomedicine (2003) 10(2-3):261-262.
4. SCHULZE J, RAASCH W, SIEGERS CP: Toxicity of kava pyrones, drug safety and precautions-a case study. Phytomedicine (2003) 10(Suppl. 4):68-73.
5. ANONYMOUS: Kava: first suspended, now prohibited. Prescrire Int. (2003) 12(66):142.
6. PITTLER MH, Ernst E: Kava extract for treating anxiety. Cochrane Database Syst. Rev. (2003)(1):CD003383.
7. BOON HS, Wong AH: Kava: a test case for Canada's new approach to natural health products. CMAJ (2003) 169(11):1163-1164.
8. SINGH YN: Kava: an overview. J. Ethnopharmacol. (1992) 37(1):13-45.
9. DOUGLAS W: The effects of heavy usage of kava on physical health. Med. J. Aust. (1988) 149:341-342.
10. ERNST E: The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann. Intern. Med. (2002) 136(1):42-53.
11. ERNST E: Second thoughts about kava. Am. J. Med. (2002) 113(4):347-348.
12. ERNST E: Recall of the herbal anxiolytic kava. Underestimation of its value or overestimation of its risks? MMW Fortschr. Med. (2002) 144(41):40.
13. ERNST E: Safety concerns about kava. Lancet (2002) 359(9320):1865.
14. PITTLER MH, ERNST E: Kava extract for treating anxiety. Cochrane Database Syst. Rev. (2002) (2):CD003383.
15. BASCH E, ULBRICHT C, HAMMERNESS P et al.: Kava monograph. J. Herbal Pharmacother. (2002) 2(4):65-91.
16. GEIER FP, KONSTANTINOWICZ T: Kava treatment in patients with anxiety. Phytother. Res. (2004) 18(4):297-300.
17. BOERNER RJ, SOMMER H, BERGER W et al.: Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder - an 8-week randomized, double-blind multi-centre clinical trial in 129 outpatients. Phytomedicine (2003) 10(Suppl. 4):38-49.
18. CAGNACCI A, ARANGINO S, RENZI A et al.: Kava-Kava administration reduces anxiety in perimenopausal women. Maturitas (2003) 44(2):103-109.
19. RUSSMANN S, LAUTERBURG BH, HELBLING A: Kava hepatotoxicity. Ann. Intern. Med. (2001) 135(1):68-69.
20. ANONYMOUS: Kava kava ruay cause irreversible liver damage. S. Afr. Med. J. (2002) 92(12):961.
21. ANONYMOUS: Concerns over kava have the FDA's attention. Mayo Clin. Health Lett. (2002) 20(7):4.
22. DE SMET PA: Safety concerns about kava not unique. Lancet (2002) 360(9342):1336.
23. ANONYMOUS: From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products-United States, Germany, and Switzerland, 1999-2002. JAMA (2003) 289(1):36-37.
24. CLOUGH AR, BAILIE RS, CURRIE B: Liver function test abnormalities in users of aqueous kava extracts. J. Toxicol. Clin. Toxicol. (2003) 41(6):821-829.
25. RUSSMANN S, BARGUIL Y, CABALION P et al.: Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur. J. Gastroenterol. Hepatol. (2003) 15(9):1033-1036.
26. ANONYMOUS: Hepatic toxicity possibly associated with kava-containing products-United States, Germany, and Switzerland, 1999-2002. MMWR Morb. Mortal. Wkly. Rep. (2002) 51(47):1065-1067.
27. BUJANDA L, PALACIOS A, SILVARINO R et al.: Kava-induced acute icteric hepatitis. Gastroenterol. Hepatol. (2002) 25(6):434-435.
28. HUMBERSTON CL, AKHTAR J, KRENZELOK EP: Acute hepatitis induced by kava kava. J. Toxicol. Clin. Toxicol. (2003) 41(2):109-113.
29. STICKEL F, BAUMULLER HM, SEITZ K et al.: Hepatitis induced by Kava (Piper methysticum rhizoma). J. Hepatol. (2003) 39(1):62-67.
30. ESCHER M, DESMEULES J, GIOSTRA E et al.: Hepatitis associated with Kava, a herbal remedy for anxiety. Br. Med. J. (2001) 322(7279):139.
31. KRAFT M, SPAHN TW, MENZEL J et al.: Fulminant liver failure after administration of the herbal antidepressant Kava-Kava. Dtsch. Med. Wochenschr. (2001) 126(36):970-972.
32. THOMSEN M, VITETTA L, SCHMIDT M et al.: Facal fulminant hepatic failure induced by a natural cherapy containing kava. Med. J. Aust. (2004) 180(4):198-199.
33. GOW PJ, CONNELLY NJ, HILL RL et al.: Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med. J. Aust. (2003) 178 (9):442-443.
34. ANONYMOUS: Relevant hepatotoxic effects of kava still need to be proven. A statement of the Society for Medicinal Plant Research. Planta Med. (2003) 69(11):971-972.
35. DENHAM A, MCINTYRE M, WHITEHOUSE J: Kava-the unfolding story: report on a work-in-progress. J. Altern. Complement Med. (2002) 8(3):237-263.
36. SCHMIDT M: Are kavalactones the hepatotoxic principle of kava extracts? The pitfalls of the glutathione theory. J. Altern. Complement Med. (2003) 9(2):183-187.
37. PARKMAN CA: Another FDA warning: Kava supplements. Case Manager (2002) 13(4):26-28.
38. CENTER FOR FOOD SAFETY AND APPLIED NUTRITION (US FOOD AND DRUG ADMINISTRATION): Kava-containing dietary supplements may be associated with severe liver injury (document issued March 25, 2002).
39. CENTER FOR FOOD SAFETY AND APPLIED NUTRITION (US FOOD AND DRUG ADMINISTRATION): Letter to health care professionals: FDA issues consumer advisory that kava products may be associated with severe liver injury (document issued March 25, 2002), contact information for FDA Medwatch program: 1-800-332-1088.
40. DE LEO V, LA MARCA A, LANZETTA D et al.: Assessment of the association of Kava-Kava extract and hormone replacement therapy in the treatment of postmenopause anxiety. Minerva Ginecol. (2000) 52(6):263-267.
41. CAWTE J: Parameters of kava used as a challenge to alcohol. Aust. NZ. J. Psychiatry (1986) 20(1):70-76.
42. GLEITZ J, FRIESE J, BEILE A et al.: Anticonvulsive action of (+/-)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sires. Eur. J. Pharmacol. (1996) 315(1):89-97.
43. SCHMITZ D, ZHANG CL, CHATTERJEE SS et al.: Effects of methysticin on three different models of seizure like events studied in rat hippocampal and entorhinal cortex slices. Naunyn Schmiedebergs Arch. Pharmacol. (1995) 351(4):348-355.
44. BAUM SS, HILL R, ROMMELSPACHER H: Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog. Neuropsychopharmacol. Biol. Psychiatry (1998) 22(7):1105-1120.
45. STEINER GG: The correlation between cancer incidence and kava consumption. Hawaii Med. J. (2000) 59(11):420-422.
46. GIRMAN A, LEE R, KLIGLER B: An integrative medicine approach to premenstrual syndrome. Am. J. Obstet. Gynecol. (2003) 188(Suppl. 5):S56-S65.
47. SINGH YN: Effects of kava on neuromuscular transmission and muscle contractility. J. Ethnopharmacol. (1983) 7(3):267-276.
48. KINZLER E, KROMER J, LEHMANN E: Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks. Arzneimittelforschung (1991) 41(6):584-588.
49. WARNECKE G: Psychosomatic dysfunctions in the female climacteric. Clinical effectiveness and tolerance of Kava Extract WS 1490. Fortschr. Med. (1991) 109(4):119-122.
50. VOLZ HP, KIESER M: Kava-kava extract WS 1490 versus placebo in anxiety disorders-a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry (1997) 30(1):1-5.
51. VOLZ HP: Kava-kava und Kavain. Münch Med. Wschr. (1997) 139:42-46.
52. PITTLER MH, ERNST E: Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J. Clin. Psychopharmacol. (2000) 20(1):84-89.
53. LEHRL S: Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. J. Affect. Disord. (2004) 78(2):101-110.
54. GASTPAR M, KLIMM HD: Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial. Phytomedicine (2003) 10(8):631-639.
55. JAPPE U, FrAnke I, REINHOLD D et al.: Sebotropic drug reaction resulting from kava-kava extract therapy: a new entity? J. Am. Acad. Dermatol. (1998) 38(1):104-106.
56. SCHMIDT P, BOEHNCKE WH: Delayed-type hypersensitivity reaction to kava-kava extract. Contact Dermatitis (2000) 42(6):363-364.
57. SUSS R, LEHMANN P: Hematogenous contact eczema caused by phytogenic drugs exemplified by kava root extract. Hautarzr (1996) 47(6):459-461.
58. SIEGERS CP, HONOLD E, KRALL B et al.: Results of the drug monitoring L 1090 with Laitan capsules. Arztl Forsch (1992) 39:7-11.
59. CAIRNEY S, MARUFF P, CLOUGH AR et al.: Saccade and cognitive impairment associated with kava intoxication. Hum. Psychopharmacol. (2003) 18(7):525-533.
60. CAIRNEY S, CLOUGH AR, MARUFF P et al.: Saccade and cognitive function in chronic kava users. Neuropsychopharmacology (2003) 28(2):389-396.
61. CLOUGH AR, JACUPS SP, WANG Z et al.: Health effects of kava use in an eastern Arnhem Land Aboriginal community. Intern. Med. J. (2003) 33(8):336-340.
62. MEYER HG: Pharmakologie der wirksamen prinzipien de kawarhizoms (Piper methysticum Forst.). Arch. Int. Pharmacodyn. Ther. (1962) 138:505-536.
63. MATHEWS JD, RILEY MD, FEJO L et al.: Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. Med. J. Aust. (1988) 148(11):548-555.
64. CLOUG H A, JONES P: Policy approaches to support local community control over the supply and distribution of kava in the Northern Territory (Australia). Drug Alcohol Rev. (2004) 23(1):117-126.
65. CLOUGH AR, WANG Z, BAILIE RS et al.: Case-control study of the association between kava rise and ischaemic heart disease in Aboriginal communities in eastern Arnhem Land (Northern Territory) Australia. J. Epidemiol. Community Health (2004) 58(2):140-141.
66. SINGH YN, SINGH NN: Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs (2002) 16(11):731-743.
67. RUZE P: Kava-induced dermopathy: a niacia deficiency? Lancet (1990) 335(8703):1442-1445.
68. KELLER F, KLOHS M: A review of the chemistry and pharmacology of the constituents of Piper methysticum. Lloydia (1963) 26:1-15.
69. STICKEL F, SEITZ HK, SCHUPPAN D: Review 'Kava, kavapyrones and toxic liver injury by R Teschke, Hanau Z. Gastroenterol. 2003, 41:395-404. Z.
70. STICKEL F, SEITZ HK, SCHUPAN D: Gastroenterol. (2003) 41(8):888-889.
71. STRAHL S, EHRET V, DAHM HH et al.: Necrotizing hepatitis after taking herbal remedies. Dtsch. Med. Wochenschr. 1998) 123(47):1410-1414.
72. NERURKAR PV, DRAGULL K, TANG CS: In vitro Toxicity of Kava Alkaloid, Pipermethystine, in HepG2 Cells as Compared to Kavalactones. Toxicol. Sci. (2004).
73. SCHERER J: Kava-kava extract in anxiety disorders: an outpatient observational study. Adv. Ther. (1998) 15(4):261-269.
74. GLEITZ J, BEILE A, WILKENS P et al.: Antithrombotic action of the kava pyrone (+)-kavain prepared from Piper methysticum on human platelets. Planta Med. (1997) 63(1):27-30.
75. DONADIO V, BONSI P, ZELE I et al.: Myoglobinuria after ingestion of extracts of guarana, Ginkgo biloba and kava. Neurol. Sci. (2000) 21(2):124.
76. HOLM E, STAEDT U, HEEP J et al.: The action profile of D,L-kavain. Cerebral sites and sleep-wakefulness- rhythm in animals. Arzneimittelforschung (1991) 41(7):673-683.
77. MUNTE TF HEINZE HJ, MATZKE M et al.: Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology (1993) 27(1):46-53.
78. GESSNER B, CNOTA P: Extract of the kava-kava rhizome in comparison with diazepam and placebo. Z. Phytother. (1994) 15(1):30-37.
79. JOHNSON D, FRAUENDORF A, STECKER K et al.: Neurophysiological active profile and tolerance of kava extract WS 1490, A pilot study with randomized evaluation. TW Neurolgie Psychiatrie (1991) 5(6):349-354.
80. HERBERG KW: Driving ability after intake of kava special extract WS 1490, a double-blind, placebo-controlled study with volunteers. Zeitschrift für Allgemeinmedizin (1991) 13:842-846.
81. HERBERG KW: Effect of Kava-Special Extract WS 1490 combined wich ethyl alcohol on safecy-relevant performance parameters. Blutalkohol (1993) 30(2):96-105.
82. ALMEIDA JC, GRIMSLEY EW. Coma from the health food score: interaction between kava and alprazolam. Ann. Intern. Med. (1996) 125(11):940-941.
83. PRESCOTT J, JAMIESON D, EMDUR N et al.: Acute effects of kava on measures of cognitive performance, physiological function and mood. Drug Alc. Rev. (1993) 12:49-58.
84. SALETU B, GRÜNBERGER J, LINZMAYER L et al.: EEG-brain mapping, psychometric and psychophysiological studies on central effects of kavain-a kava plant derivative. Hum. Psychopharm. (1989) 4:169-190.
85. RADUEGE KM, KLESHINSKI JF, RYCKMAN JV et al.: Anesthetic considerations of the herbal, kava. J. Clin. Anesth. (2004) 16(4):305-311.
86. PATRA KK, COFFEY CE: Implications of herbal alternative medicine for electroconvulsive cherapy. J. ECT (2004) 20(3):186-194.
87. SCHELOSKY L, RAFFAUF C, JENDROSKA K et al.: Kava and dopamine antagonism. J. Neurol. Neurosurg. Psychiatry (1995) 58(5):639-640.
88. MESEGUER E, TABOADA R, SANCHEZ V et al.: Life-threatening parkinsonism induced by kava-kava. Mov. Disord. (2002) 17(1):195-196.
89. SPILLANE PK, FISHER DA, CURRIE BJ: Neurological manifestations of kava intoxication. Med. J. Aust. (1997) 167(3):172-173.
90. SIBON I, ROSIER E, ORGOGOZO JM: Meningismus after taking kava-kava. Rev. Neurol. (Paris) (2002) 158(12):1205-1206.
91. GARNER LF, KLINGER JD: Some visual effects caused by the beverage kava. J. Ethnopharmacol. (1985) 13(3):307-311.
92. LEUNG N: Acute urinary retention secondary to kava ingestion. Emerg. Med. Australas. (2004) 16(1):94.
93. JAMIESON DD, DUFFIELD PH: Positive interaction of ethanol and kava resin in truce. Clin. Exp. Pharmacol. Physiol. (1990) 17(7):509-514.
94. JAMIESON DD, DUFFIELD PH: The antinociceptive actions of kava components in mice. Clin. Exp. Pharmacol. Physiol. (1990) 17(7):495-507.
95. MURPHY JM: Preoperative considerations with herbal medicines. AORN J. (1999) 69 (1):173-8, 180.
96. SPARREBOOM A, COX MC, ACHARYA MR et al.: Herbal remedies in the United States: potential adverse interactions with anticancer agents. J. Clin. Oncol. (2004) 22(12):2489-2503.
97. UEBELHACK R, FRANKE L, SCHEWE HJ: Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry (1998) 31(5):187-192.
98. MATHEWS JM, ETHERIDGE AS, BLACK SR: Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab. Dispos. (2002) 30(11):1153-1157.
99. UNGER M, HOLZGRABE U, JACOBSEN W et al.: Inhibition of cytochrome P450 3A4 by extracts and kavalaciones of Piper methysticum (Kava-Kava). Planta Med. (2002) 68(12):1055-1058.
100. ANKE J, RAMZAN I: Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.). J. Ethnopharmacol. (2004) 93(2-3):153-160.
101. ANKE J, RAMZAN I: Kava Hepatotoxicity: Are we any closer to the truth? Planta Med. (2004) 70(3):193-196.
102. ZOU L, HENDERSON GL, HARKEY MR et al.: Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine (2004) 11(4):285-294.
103. ZOU L, HARKEY MR, HENDERSON GL et al.: Kava does not display metabolic toxicity in a homogeneous cellular assay. Planta Med. (2004) 70(4):289-292.
104. BOERNER RJ, KLEMENT S: Attenuation of neuroleptic-induced extrapyramidal side effects by Kava special extract WS 1490. Wien. Med. Wochenschr. (2004) 154(21-22):508-510.
105. DAVIES LP, DREW CA, DUFFIELD P et al.: Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacol. Toxicol. (1992) 71(2):120-126.
106. JUSSOFIE A, SCHMIZ A, HIEMKE C: Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl) (1994) 116(4):469-474.
107. JAMIESON DD, DUFFIELD PH, CHENG D et al.: Comparison of the central nervous system activity of the aqueous and lipid extract of kava (Piper methysticum). Arch. Int. Pharmacodyn. Ther. (1989) 301:66-80.
108. BECKMAN SE, SOMMI RW, SWITZER J: Consumer use of St. John's wort: a survey on effectiveness, safety, and tolerability. Pharmacotherapy (2000) 20(5):568-574.
109. DUFFIELD AM, LIDGARD RO, LOW GK: Analysis of the constituents of Piper methysticum by gas chromatography methane chemical ionization mass spectrometry. New constituents of kava resin. Biomed. Environ. Mass Spectr. (1986) 13:305-313.
110. DUFFIELD AM, LIDGARD RO: Analysis of kava resin by gas chromatography and electron impact and methane negative ion chemical ionization mass spectrometry. New trace constituents of kava resin. Biomed. Environ. Mass Spectr. (1986) 13:621-626.
111. DUVE RN: Gas-liquid chromatographic determination of major constituents of Piper methysticum. Analyst (1981) 106:160-165.
112. KLOHS MW, KELLER F, WILLIAMS RE et al.: A chemical and pharmacological investigation of Piper methysticum Forst. J. Med. Pharm. Chem. (1959) 1(1):95-103.
113. SMITH RM: Kava lactones in Piper methysticum from Fiji. Phytochemistry (1983) 22:1055-1056.
114. SMITH RM, THAKRAR H, AROWOLO A et al.: High-performance liquid chromatography of kava lactones from Piper methysticum. J. Chromatography (1984) 283:303-308.
115. YOUNG RL, HYLIN JW, PLUCKNETT DL et al.: Analysis for kawa pyrones in extracts of piper methysticum. Phytochemistry (1966) 5:795-798.
116. BRÜGGEMANN F, MEYER HJ: Die analgetische wirkung der Kawa-inhaltsstoffe dihydrokawain und dihydromethysticin. Arzneimittelforschung (1963) 13:407-409.
117. HÄNSEL R: Characterization and physiological activity of some Kawa constituents. Pacific Science (1968) 22:293-313.
118. KRETZSCHMAR R, Meyer HJ: Comparative studies on the anticonvulsant activity of the pyrone compounds of Piper methysticum Forst. Arch. Int. Pharmacodyn. Ther. (1969) 177(2):261-277.
119. KRETZSCHMAR R, MEYER HJ, TESCHENDORF HJ et al.: Antagonistic action of natural 5,6-hydrogenated Kava pyrones against strychnine poisoning and experimental local tetanus. Arch. Int. Pharmacodyn. Ther. (1969) 182(2):251-268.
120. KRETZSCHMAR R, MEYER HJ, TESCHENDORF HJ: Strychnine antagonistic potency of pyrone compounds of the kavaroor (Piper methysticum Forst.). Experientia (1970) 26(3):283-284.
121. KRETZSCHMAR R, TESCHENDORF HJ, LADOUS A et al.: On the sedative action of the kava rhizome (piper methyst.). Acta Pharmacol. Toxicol. (1971) 29(4):26.
122. MEYER HJ: Spasmolytic effect of dihydromechysticin, a constituent of Piper methysticum Forst. Arch. Int. Pharmacodyn. Ther. (1965) 154(2):449-467.
123. MEYER HJ, MEYER-BURG J: Hemmung des elektrokrampfes durch die kawa-pyrone dihydromethysticin und dihydrokawain. Arch. Int. Pharmacodyn. (1964) 148(1-2):97-110.
124. SINGH Y, BLUMENTHAL M: Kava: an overview. Distribution, mythology, botany, culture, chemistry and pharmacology of the South Pacific's most revered herb. HerbalGram (1997) 39(Suppl. 1):34-56.
125. BACKHAUSS C, KRIEGLSTEIN J: Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. Eur. J. Pharmacol. (1992) 215(2-3):265-269.
126. KLEISER B, DIEPERS M, WAGNER N et al.: Treatment of intracerebral hematomas with kava in rats. Neurology (1998) 50(4):a398.
127. WALDEN J, VON WEGERER J, WINTER U et al.: Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Prog. Neuropsychopharmacol. Biol Psychiatry (1997) 21(4):697-706.
128. WALDEN J, VON WEGERER J, WINTER U et al.: Actions of kavain and dihydromethysticin on ipsapirone-induced field potential changes in the hippocampus. Human Psychopharm. (1997) 12:265-270.
129. + channels. Planta Med. (1996) 62:580-581.
130. GLEITZ J, BEILE A, PETERS T: (+/-)-kavain inhibits the veratridine- and KCl-induced increase in intracellular Ca2+ and glutamate-release of rat cerebrocortical synaptosomes. Neuropharmacology (1996) 35(2):179-186.
131. SEITZ U, SCHULE A, GLEITZ J: [3H]-monoamine uptake inhibition properties of kava pyrones. Planta Med. (1997) 63(6):548-549.
132. EMSER W, BARTYLLA K: Improvement of sleep quality. Effect of kava extract WS 1490 on the sleep pattern in healthy subjects. Neurologie/Psychiatrie (1991) 5(11):636-642.
133. BOONEN G, FERGER B, KUSCHINSKY K et al.: In vivo effects of the kavapyrones (+)-dihydromechysticin and (+/-)- kavain on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions. Planta Med. (1998) 64(6):507-510.
134. BUCKLEY JP, FURGIUELE AR, O'HARA MJ: Pharmacology of kava. Ethnopharm. Search Psych. Drugs (1967) 1:141-151.
135. FURGIUELE AR, KINNARD WJ, ACETO MD et al.: Central activity of aqueous extracts of Piper methysticum (kava). J. Pharm. Sci. (1965) 54:247-252.
136. DUFFIELD PH, JAMIESON D: Development of tolerance to kava in mice. Clin. Exp. Pharmacol Physiol. (1991) 18(8):571-578.
137. DUFFIELD AM, JAMIESON DD, LIDGARD RO et al.: Identification of some human urinary metabolites of the intoxicating beverage kava. J. Chromatogr. (1989) 475:273-281.
138. DUFFIELD PH, JAMIESON DD, DUFFIELD AM: Effect of aqueous and lipid-soluble extracts of kava on the conditioned avoidance response in rats. Arch. Int. Pharmacodyn. Ther. (1989) 301:81-90.
139. BfArM notice to manufactures May 2005.